Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05957198 · ClinicalTrials.gov registry record
Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
A clinical trial of Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 114,921
- Enrollment target
- 1
- Study location
NCT05957198: Completed study of Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim.
NCT05957198 is a study of Lung Diseases, Interstitial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 114,921 participants, above the 1,016-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (11211% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05957198, a study of Lung Diseases, Interstitial, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 114,921 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to describe initiation and use of oxygen therapy among patients with fibrotic Interstitial Lung Disease (ILD) and to assess the impact of oxygen therapy on clinical outcomes among patients with fibrotic ILD.
Primary Outcome
Time from the fibrosing Interstitial Lung Disease (ILD) diagnosis date to oxygen therapy initiation is reported. Descriptive statistics are rounded to one decimal place.
Conditions Studied
Study Locations (1)
Connecticut
- Boehringer Ingelheim Pharmaceuticals, Inc. - Ridgefield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114,921 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2023-09-26 |
What the finished NCT05957198 record still lists
NCT05957198 is an observational study that tracks outcomes without assigning an intervention. Its 114,921 participants enrollment target places it among the larger protocols in the corpus, above the 1,016-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (11211% higher).
The record links to 1 condition, with Lung Diseases, Interstitial appearing as the primary indexed condition, and to 0 interventions.
NCT05957198 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05957198 about?
NCT05957198 is a clinical study titled "Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease". The purpose of this study is to describe initiation and use of oxygen therapy among patients with fibrotic Interstitial Lung Disease (ILD) and to assess the impact of oxygen therapy on clinical outcomes among patients with fibrotic ILD.
What is the current status of trial NCT05957198?
This trial is currently completed. The enrollment target is 114,921 participants. The study started on 2023-07-25. Estimated completion is 2023-09-26.
What conditions does trial NCT05957198 study?
This clinical trial studies the following conditions: Lung Diseases, Interstitial.
Who is sponsoring clinical trial NCT05957198?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05957198 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases, Interstitial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05957198's enrollment target sits among peer trials
114,921 1st of 10 higher than 10 of 10 other Lung Diseases, Interstitial trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Diseases, Interstitial trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RECRUITING · Phase 3
-
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RECRUITING
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
-
Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease
RECRUITING · Phase 1
-
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
RECRUITING · NA
-
Cough Capture as a Portal Into the Lung
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06251323 · 119,680 participants · NA
Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)
- NCT03897374 · 120,000 participants
Strategic Targeting for Optimal Prevention of Cancer
- NCT06608758 · 120,000 participants
End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
- NCT05804188 · 105,000 participants
CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI